Andrographis, a herb once popular in cold and flu remedies, is now under scrutiny in Australia due to its potential for severe allergic reactions and even death. The Therapeutic Goods Administration (TGA) has proposed removing Andrographis from its list of permitted ingredients, citing a lack of empirical evidence supporting its benefits and the risk of anaphylaxis. This proposal comes after years of adverse event reports, including anaphylaxis and drug-induced liver injury, despite changes to labelling and product availability. The TGA's safety review highlights the unpredictable nature of these reactions, which can occur even in individuals without a history of allergies or asthma. The herb's popularity, particularly during the COVID pandemic, has led to increased scrutiny, with the TGA recommending that consumers read updated safety reviews and seek medical advice if experiencing any symptoms of an allergic reaction. This case raises important questions about the safety of herbal supplements and the need for robust regulatory oversight to protect public health.
